| Type | Public |
| HQ | San Diego, US |
| Founded | 2008 |
| Size (employees) | 139 (est) |
| Website | otonomy.com |
Otonomy was founded in 2008 and is headquartered in San Diego, US
Report incorrect company information
Viewing summary data as a guest
Sign up for free to see all dataKey People/Management at Otonomy
Paul E. Cayer
Chief Financial and Business Officer
Report incorrect company information
Otonomy Office Locations
Otonomy has an office in San Diego
San Diego, (HQ)
6275 Nancy Ridge Dr
Report incorrect company information
Otonomy Financials and Metrics
Otonomy Revenue
Otonomy's revenue was reported to be $1.24 m in FY, 2017
| USD | |
|---|---|
Revenue (Q3, 2018) | 113.0k |
Gross profit (Q3, 2018) | (49.0k) |
Gross profit margin (Q3, 2018), % | (43.4%) |
Net income (Q3, 2018) | (12.5m) |
EBIT (Q3, 2018) | (13.0m) |
Market capitalization (4-Dec-2018) | 72.0m |
Closing stock price (4-Dec-2018) | 2.4 |
Cash (30-Sep-2018) | 21.4m |
Otonomy's current market capitalization is $72 m.
- Source: SEC Filings
Annual
Quarterly
| USD | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|
Revenue | 13.0k | 76.0k | 321.0k | 358.0k | 326.0k | 282.0k | 301.0k | 123.0k | 113.0k |
Cost of goods sold | 9.0k | 395.0k | 351.0k | 463.0k | 397.0k | 290.0k | 272.0k | 241.0k | 162.0k |
Gross profit | 4.0k | (319.0k) | (30.0k) | (105.0k) | (71.0k) | (8.0k) | 29.0k | (118.0k) | (49.0k) |
Gross profit Margin, % | 31% | (420%) | (9%) | (29%) | (22%) | (3%) | 10% | (96%) | (43%) |
- Source: SEC Filings
Annual
Quarterly
| USD | Q3, 2014 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 165.2m | 190.3m | 176.6m | 244.3m | 46.6m | 19.8m | 13.7m | 22.3m | 16.9m | 23.2m | 19.0m | 21.4m |
Accounts Receivable | 146.0k | 2.0k | 87.0k | 178.0k | 76.0k | 126.0k | 133.0k | 14.0k | 45.0k | |||
Inventories | 614.0k | 913.0k | 1.7m | 1.2m | 1.2m | 1.2m | ||||||
Current Assets | 167.3m | 216.1m | 204.4m | 270.7m | 245.6m | 222.7m | 173.6m | 155.3m | 139.5m | 112.7m | 102.4m | 95.0m |
Annual
Quarterly
| USD | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 |
|---|---|---|---|---|---|---|---|---|---|
Net Income | (29.7m) | (27.6m) | (27.1m) | ||||||
Inventories | 614.0k | 913.0k | 1.7m | 1.2m | 1.2m | ||||
Accounts Payable | 1.7m | 1.9m | 4.0k | 2.1m | 2.4m | 800.0k | 934.0k | 212.0k | 1.3m |
| USD | Y, 2018 |
|---|---|
Financial Leverage | 1.1 x |
Otonomy Operating Metrics
| FY, 2016 | |
|---|---|
Patents Pending | 115 |
Phase II Trials Products | 2 |
Phase III Trials Products | 2 |
Preclinical Phase Products | 1 |
Report incorrect company information
Otonomy Online and Social Media Presence
251 Twitter followers
Otonomy has 251 Twitter Followers. The number of followers has decreased 0.9% month over month and decreased 3.1% quarter over quarter
Report incorrect company information
Otonomy News and Updates
August 08, 2018
Otonomy Reports Second Quarter 2018 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. EDT Conference call and webcast today at 4:30 p.m. EDT
December 07, 2017
Ultimate Analysis on Meniere ’s disease Market & Global Forecast to 2023
Meniere’s disease market Analysis, by diagnosis (hearing assessment, balance assessment, and others), by treatment (medication, surgery, and others), by end user & is to Grow with USD 6380.3 Million, 8.5% of CAGR Posted via Industry Today. Follow us on Twitter @IndustryToday
November 14, 2017
Magnificent Expansion of Meniere ’s disease Market: Valuation USD 6380.3 Million, 8.5% of CAGR By 2023
Market Research Future published a research report on “Meniere’s Disease Market Research Report- Global Forecast till 2023“– Market Analysis, Scope, Stake, Progress, Trends and Forecast to 2023. Posted via Industry Today. Follow us on Twitter @IndustryToday
Report incorrect company information
Otonomy Blogs
November 15, 2018
Otonomy to Participate in Piper Jaffray 30th Annual Healthcare Conference
SAN DIEGO , Nov. 15, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced that David A. Weber , Ph.D., president and chief executive officer, will participate in a fireside chat at
November 06, 2018
Otonomy Presents Data Highlighting Potential of OTO-413, an Otic Sustained-Exposure Formulation of BDNF, to Treat Hearing Loss
Society for Neuroscience Features OTO-413 Presentation as Neuroscience 2018 Hot Topic SAN DIEGO , Nov. 06, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today is presenting data on the
November 05, 2018
Otonomy Reports Third Quarter 2018 Financial Results and Provides Corporate Update
Conference call and webcast today at 4:30 p.m. EST Conference call will include review of OTO-413 program selected as "Hot Topic" at Society for Neuroscience Annual Meeting SAN DIEGO , Nov. 05, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the
October 30, 2018
Otonomy Announces Multiple Presentations at Society for Neuroscience Annual Meeting including OTO-413 Presentation Selected as "Hot Topic"
SAN DIEGO , Oct. 30, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced multiple presentations related to the company's programs in hearing loss and tinnitus at the upcoming Society
October 29, 2018
Otonomy to Report Third Quarter 2018 Financial Results and Provide Corporate Update
Webcast and Conference Call to be Held at 4:30 p.m. EST on November 5, 2018 SAN DIEGO , Oct. 29, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for otology, today announced it will report financial results
October 02, 2018
Otonomy Announces OTIVIDEX™ Data Presentation at American Academy of Otolaryngology - Head and Neck Surgery Foundation Annual Meeting
Positive Results from AVERTS-2 Phase 3 Clinical Trial will Support Submission for U.S. Registration and Provide Basis for Ongoing Additional Phase 3 Trial SAN DIEGO , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Otonomy , Inc. (NASDAQ: OTIC), a biopharmaceutical company dedicated to the development of
Otonomy Company Life and Culture
Report incorrect company information
Otonomy Frequently Asked Questions
When was Otonomy founded?
Otonomy was founded in 2008.
Who are Otonomy key executives?
Otonomy's key executives are Paul E. Cayer.
How many employees does Otonomy have?
Otonomy has 139 employees.
What is Otonomy revenue?
Latest Otonomy annual revenue is $1.2 m.
What is Otonomy revenue per employee?
Latest Otonomy revenue per employee is $8.9 k.
Who are Otonomy competitors?
Competitors of Otonomy include Kiniksa Pharmaceuticals, Sartorius Stedim BioOutsource and Neurosearch.
Where is Otonomy headquarters?
Otonomy headquarters is located at 6275 Nancy Ridge Dr, San Diego.
Where are Otonomy offices?
Otonomy has an office in San Diego.
How many offices does Otonomy have?
Otonomy has 1 office.